All issues > Volume 0(0);

Original Article

Published online: August 6, 2025

DOI: https://doi.org/10.3345/cep.2025.01011

Serum copper and ceruloplasmin levels as biomarkers reflecting liver fibrosis in children with autoimmune hepatitis

Salma Abdel Megeed Nagi, MD^1,2, Mai Ibrahim Elashmawy, MD³, Amany E. Elashkar, MD³, Mohamed Zaeim Hafez, MD⁴, Ashraf A.E. Emara, MD⁵, Osama Mohammad Abdelhay, MD⁵, Albayoumi A.B. Fouda, MD⁵, Mohamed AbdelAziz Doma, MD⁶, Ahmad Mohamed Awad, MD⁶, Ahmed Mohammed Saba, MD⁶, Hesham Abdelrahman Ahmed, MD⁷, Ahmed Mohamed Gad Allah, MD⁸, Fatma Mahmoud Abdelraheem, MD⁹, Mohamed A. Gad, MD¹⁰, Mohamad A. Soliman, MD¹¹, Tamer I. Abdalrhman, MD¹¹, Khaled Hassaan Awad, MD¹², Ismael A.K.M. El-lebedy, MD¹², Mostafa M. Abdelnaser, MD¹³, Mohammed Z. Abdel Kareem, MD¹³, Marwa Fekry Hassan, MD¹⁴, Shymaa Sobhy Menshawy Khalifa, MD¹⁵

¹Faculty of Medicine, King Salman International University, South Sinai, Egypt

²Pediatric Hepatology, Gastroenterology, and Nutrition Department, National Liver Institute, Menoufia University, Shebin ElKom, Egypt

³Clinical Pathology Department, National Liver Institute, Menoufia University, Shebin ElKom, Egypt

⁴Medical Physiology Department, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

⁵Medical Physiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

⁶Medical Biochemistry Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

⁷Medical Biochemistry Department, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

⁸Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

⁹Histology and Cell Biology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

¹⁰Medical Biochemistry Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt

¹¹Medical Histology and Cell Biology Department, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

¹²Pediatric Department, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

¹³Medical Microbiology and Immunology Departments, Faculty of Medicine, Al-Azhar University (Assiut), Assiut, Egypt

¹⁴Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menoufia, Egypt

¹⁵Pediatrics Department, Faculty of Medicine, Menoufia University, Shebin ElKom, Egypt

Corresponding author: Salma Abdel Megeed Nagi, MD. Faculty of Medicine, King Salman International University, El Tor Branch, Sahely Road, South Sinai, Shebin ElKom 32511, Egypt Email: salmanage@liver.menofia.edu.eg

Received May 4, 2025       Revised June 11, 2025       Accepted June 11, 2025

Copyright © 2025 by The Korean Pediatric Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Background

Clinical, biochemical, histological, and immunological indicators are frequently used to diagnose autoimmune hepatitis (AIH), a chronic inflammatory liver disease affecting children. Wilson disease, which resembles AIH, is mainly evaluated using serum ceruloplasmin and copper levels. However, changes in these biomarkers have also been observed in AIH, raising the question of whether they could be useful for evaluating children with AIH.

Purpose

Purpose

When selecting a treatment plan and estimating the long-term prognosis of patients with AIH, assessing the liver fibrosis stage is crucial. It is also crucial to identify noninvasive indicators of liver fibrosis, for which ceruloplasmin has been suggested as a biomarker in several liver diseases. Therefore, this study aimed to investigate the potential significance of serum ceruloplasmin and copper levels for identifying liver fibrosis in children with AIH.

Methods

Methods

One hundred children with AIH treated at Menoufia University’s National Liver Institute Pediatric Hepatology, Gastroenterology, and Nutrition Department were enrolled. The duration of the study was 5 years (February 2020 to February 2025). The patients' histopathological, radiographic, laboratory, and clinical data were collected. We used the revised score to diagnose AIH. A Beckman Coulter AU480 chemistry analyzer was used to measure serum copper, while an enzyme-linked immunosorbent assay was used to measure serum ceruloplasmin.

Results

Results

Serum ceruloplasmin levels were considerably lower in patients with advanced fibrosis (F3–4) than in those without advanced fibrosis (F0–2) (P<0.001). However, in patients with extensive fibrosis, the serum copper levels were considerably elevated (P<0.001). Compared to serum copper level, which had an area under a curve of 0.939 (95% confidence interval [CI], 0.887–0.991; P<0.001) and a cutoff of >24.7 mg/dL (90.8% sensitivity, 66.9% specificity), ceruloplasmin level had an area under a curve of 0.945 (95% CI, 0.889–1.00; P<0.001), suggesting that it could be a useful tool for the detection of advanced liver fibrosis in children.

Conclusion

Conclusion

To estimate the long-term prognosis of patients with AIH, it is crucial to assess liver fibrosis stage. It is crucial to identify noninvasive indicators of liver fibrosis, for which ceruloplasmin has been suggested as a biomarker. Therefore, serum copper and ceruloplasmin levels may provide important information for the identification of advanced liver fibrosis in children with AIH.

Key words: Autoimmune hepatitis, Ceruloplasmin, Liver fibrosis, Serum copper, Wilson disease

Key message

· A total of 159 children with autoimmune hepatitis (AIH; 60.3% female, 13.2% type 2 AIH) were identified. According to a global study, the estimated annual incidence of AIH in Egypt is 1.28 cases per 100,000 inhabitant-years.

· No studies to date have examined the serum levels of copper or ceruloplasmin in children with AIH. Therefore, here we investigated whether serum copper and ceruloplasmin levels are useful for identifying liver fibrosis in children with AIH.

· Serum copper and ceruloplasmin levels may provide important information for the identification of advanced liver fibrosis in children with AIH.

Introduction

Introduction

According to Beretta-Piccoli et al. [1] and Yu et al. [2], autoimmune hepatitis (AIH) is an immune-mediated hepatocyte damage that results in inflammation, liver failure, and fibrosis by destroying liver cells. AIH in children is an autoimmune inflammatory illness that typically necessitates long-term immunosuppression. Current medications do not suppress intrahepatic immunological processes, as evidenced by the frequent relapses following therapy withdrawal [3,4].

There is no discernible pattern of genetic susceptibility or recognizable environmental impacts for AIH, even though there appear to be some regional variations [5]. Female predilection raised aminotransferase levels, hypergammaglobulinemia or elevated immunoglobulin G (IgG) levels, positive results for autoimmune antibodies, and interface hepatitis on biopsy are the typical characteristics of AIH. An autoimmune attack on the liver may be caused by a combination of genetic predisposition, environmental stimuli, and immunological tolerance mechanisms failing [6].

Elevated liver enzymes, autoantibody positivity, IgG elevation, compatible or typical liver histology results, and ruling out other liver disease causes are the basis for the diagnosis [7]. The likelihood of developing AIH is increased by extrahepatic autoimmunity and/or a family history of autoimmune disorders. Interface hepatitis, plasma cell-rich infiltrates, emperipolesis, and rosette formation are the most common histological findings [8,9]. However, only 56% of infants with AIH had all these histological characteristics, and histological results are not always definitive, particularly when the disease is still in its early stages [10]. In addition to the serological characteristics, new criteria were recently proposed for the histological diagnosis of AIH; however, these are still awaiting validation [11]. Additionally, several illnesses could be mistakenly labeled as AIH since they appear in children [12-15].

One essential trace element is copper. It functions as a cofactor for enzymes that are involved in fibrogenesis, antioxidant defense, and cellular energy metabolism. Few studies have linked these processes to changes in copper levels, even though they are essential to the pathophysiology of many liver illnesses [6]. The primary protein in the blood that carries copper is called ceruloplasmin (CP). Non-copper-bound apo-CP degrades quickly due to the copper transportation problem [16]. Numerous liver illnesses are linked to abnormalities in CP function and metabolism [17]. The purpose of this study was to determine whether serum CP and copper play a part in determining liver fibrosis in child with AIH.

Methods

Methods

1. Study design and patient setting

1. Study design and patient setting

This is a prospective study to determine if blood copper and serum CP play a factor in identifying liver fibrosis in children with AIH. This study was carried out on 100 children who had been diagnosed with the disease at the Pediatric Hepatology, Gastroenterology, and Nutrition Department, National Liver Institute, Menoufia University during 5 years from February 2020 till February 2025. Based on their autoantibody profiles, the patients were divided into 3 groups as type 2 AIH is characterized by the presence of liver kidney microsomal (LKM) antibodies, type 1 AIH is characterized by the presence of antinuclear anti-smooth muscle antibodies (ASMA) and antinuclear antibodies (ANA), and seronegative AIH is diagnosed based on histological and clinical findings even in the absence of typical autoantibodies.

2. Patients’ selection criteria

2. Patients’ selection criteria

Children under the age of eighteen who had been diagnosed with AIH and had positive autoantibodies (ANA, ASMA, and LKM) as well as a liver biopsy and clinical evaluation were eligible to be included. Nevertheless, the study did not include children with metabolic liver abnormalities, Wilson disease, or viral hepatitis. When circulating antibodies, combined with distinctive histologic abnormalities (interface hepatitis) and laboratory and clinical symptoms (elevated alanine aminotransferase [ALT]; aspartate aminotransferase [AST], and serum IgG), are present, AIH can be diagnosed. Since AIH lacks a pathognomonic sign, diagnosing it necessitates ruling out other liver conditions that might be similar. Hepatocellular patterns predominate in the normal biochemical profile of AIH, with bilirubin and aminotransferase concentrations ranging from slightly over upper limit normal to more than 50 times these levels. In most cases, cholestatic enzymes are either normal or slightly elevated. AIH is characterized by autoantibodies, which are crucial for diagnosis and cholestasis cases not included [18].

3. Sample size estimation

3. Sample size estimation

The sample was estimated using data from a prior study that showed each subject group's responses were normally distributed, with a standard deviation of 42 [19]. To reject the null hypothesis that the means of the experimental and control groups were equal with probability (power) 0.80, we examined 39 experimental participants and 39 control subjects if the true difference between the experimental and control means is 35. This test of the null hypothesis has a type 1 error probability of 0.05. After a 10% dropout rate, there were 100 patients in the entire sample.

4. Ethical consideration

4. Ethical consideration

The authors affirm that the work described was completed in accordance with the World Medical Association's Declaration of Helsinki. The Ethical Committee of the Faculty of Medicine, Al-Azhar University (RESERACH/AZ.AST. /PHY003/11/239/1/2025) and the local committee of the National Liver Institute, Menoufia University (NLI IRB: 00014014/FWA00034015/00689/2025) approved all study procedures. The benefits, potential hazards, and each stage of the process were explained to each participant. Before joining the study, they all signed a written informed consent form.

All the patients studied were subjected to gather clinical and demographic information, such as gender and age.

Laboratory workup The Sysmex KX-21 automated hematology analyzer (Sysmex Corp., Japan) provides a complete blood image along with a differential leucocytic count. The Sysmex XT Automated Hematology Systems leverage the capabilities of hydrodynamic focusing and fluorescence flow cytometry. A Cobas 6000 analyzer (c501 module, Roche Diagnostics) was used to perform kidney functions (urea, creatinine) and liver biochemical tests (ALT, AST, total and direct bilirubin, serum albumin). Roche Diagnostics' Cobas 6000 analyzer (e601 module) was used to screen for viral hepatitis (hepatitis C [HCV] and hepatitis B [HBV]), ANA, ASMA, and LKM autoantibodies (NOVA Lite ANA KSL kit, Inova Diagnostics, USA), in accordance with the guidelines provided by the manufacturer. The Olympus BH2-RFL-T3 fluorescence microscope was used to read the slides. An L3-12 high-frequency linear probe was used to perform abdominal ultrasonography on a GE Logic P9 ultrasound machine.

5. Liver biopsy

5. Liver biopsy

As seen in Fig. 1A–D, Masson’s trichrome and hematoxylin and eosin (H&E) were used to stain all liver biopsies from patients who had undergone treatment prior to treatment. To determine the stage of liver fibrosis and grade the level of inflammation, the Ishak score was employed. We took liver biopsies before starting treatment for AIH. The duration of AIH before biopsy was around 2 weeks till 1 month.

6. Blood sample collection

6. Blood sample collection

All subjects had their blood drawn into serum separator tubes, which were then centrifuged, aliquoted, and frozen. Before analysis, the samples were kept at -80°C

1) CP enzyme-linked immunosorbent assay

1) CP enzyme-linked immunosorbent assay

The Human CP ELISA (enzyme-linked immunosorbent assay) Kit (Wuxi Donglin Sci & Tech Development Co., Ltd., China) was used to measure serum CP. The assay process was carried out in compliance with the guidelines provided by the manufacturer. The kit's detection limits and sensitivity were 0.625–40 ng/mL and 0.283 ng/mL, respectively.

2) Copper assay

2) Copper assay

The serum copper levels were measured using Beckman Coulter Au480.

7. Statistical analysis

7. Statistical analysis

The data was collected, tabulated, and statistically analyzed using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA). Quantitative data presented as median, and range is known as descriptive statistics. To examine the association between qualitative characteristics, the study employed the chi-square test. If more than 20% of the cells have an anticipated count of less than 5, use the Monte Carlo correction for the chi-square test or Fisher exact test. Two normally distributed datasets are compared using quantitative variables using the Student t test. Quantitative variables were compared between 2 nonnormally distributed data groups using the Mann-Whitney U test. The receiver operating characteristic (ROC) analysis test plots sensitivity against (1-specificity) of a classification test to evaluate the accuracy of model predictions, while the analysis of variance F test compares variances across the means (or average) of several groups. P values less than 0.05 are regarded as significant.

Results

Results

A flowchart of the 109 children was enrolled in the current study who were first diagnosed with AIH at Menoufia University's National Liver Institute's Pediatric Hepatology Department. 100 people took part in the trial, and 9 patients were eliminated (3 patients refused consent, and 6 did not fit the inclusion criteria). Patients were divided into 3 categories based on their autoantibody profiles: seronegative AIH (n=16), AIH type 1 (n=75), and AIH type 2 (n=9). Additional classification was carried out according to the stage of fibrosis, with stages 3 and 4 being regarded as advanced fibrosis (Fig. 2).

According to the results of liver biopsy analysis, the patients under study were divided into 2 groups: those with advanced fibrosis and those without. 84 of the 100 AIH patients (84%) had nonadvanced liver fibrosis, while 16 (16%) had advanced fibrosis. Females made up 87.5% of patients with advanced fibrosis and 61% of all AIH patients. However, only 39% of AIH patients and 12.5% of patients with severe fibrosis were males. Patients with advanced fibrosis were statistically significantly more likely to be female (P=0.018). At diagnosis, the average age was 8.03±4.27. In terms of laboratory markers, individuals with extensive fibrosis had significantly lower levels of Hb, ALT, AST, and CP (P=0.019, P=0.043, P=0.013, and P<0.001, respectively). Patients with advanced fibrosis had considerably higher copper levels (P<0.001)(Fig. 3). Regarding the kind of AIH and other laboratory characteristics, no notable variations were found, as shown in Table 1.

Patients were divided into 3 categories based on autoantibody results: seronegative AIH, AIH type 1, and AIH type 2. Nine of the 100 individuals (9%) with AIH had type 2 AIH, 16 (16%) had seronegative AIH, and 75 (75%) had type 1 AIH. Table 2 shows basic laboratory, clinical, and demographic data. Except for type 2 AIH having a considerably lower CP level than type 1 and seronegative groups (P=0.024 and P=0.011, respectively), there were no discernible differences between the various forms of AIH. According to Table 2, the levels of CP were 16.22±2.81 in type 2 AIH, 20.42±5.07 in type 1 AIH, and 21.81±6.63 in seronegative AIH.

Regarding ultrasonography examination, there were no appreciable differences between the forms of AIH under study (P>0.05). Nonetheless, there were notable variations in the fibrosis stage when taking histological findings into account (P=0.026). Seronegative AIH had a substantially higher prevalence of mild fibrosis (n=8, 50%), but type 1 and type 2 AIH had higher prevalences of intermediate fibrosis (n=38, 50.6%; n=6, 66.6%, respectively). The prevalence of severe (advanced) fibrosis was higher in type 2 AIH (n=3, 33.3%), seronegative AIH (n=4, 25%), and type 1 AIH (n=9, 12%) (Table 3).

The levels of total and direct bilirubin, AST, and PLTs were significantly positively correlated with CP (r=0.20, P=0.042, r=0.21, P=0.033, r=0.20, P=0.040, and r=0.32, P=0.001, respectively). Serum copper levels and both total and direct bilirubin showed a strong positive connection (r=0.20, P=0.042, and r=0.21, P=0.033, respectively). Serum copper levels and AST showed a strong negative connection (r=-0.22, P=0.023) (Table 4).

The risk variables for progressive liver fibrosis in AIH patients were calculated using binary logistic regression analysis (Table 5). In the univariate logistic regression analysis, patients with advanced liver fibrosis were more likely to be female (P=0.03), have greater serum copper (P=0.004), lower CP levels (P=0.005), higher ALT (P=0.029), and higher AST (P=0.024). However, CP and copper levels were found to be independent risk factors for predicting advanced liver fibrosis in AIH patients following multivariate logistic regression analysis. The odds ratios (ORs) were 2.71 (95% confidence interval [CI], 1.263–5.796; P=0.010) and 0.30 (95% CI, 0.119–0.757; P=0.011), respectively (Table 5).

In contrast to serum copper levels, which have an area under the curve of 0.939 at 95% CI (0.887–0.991, P<0.001), with a cutoff of >24.7 mg/dL with 90.8% sensitivity and 66.9% specificity, CP levels in our study had an area under the curve of 0.945 at 95% CI of (0.889–1.00, P<0.001) with a cutoff of <17.5 ng/mL with 97.3% sensitivity and 61.5% specificity (Fig. 4).

Except for sex (P=0.019), there was no significant correlation between the CP levels and the factors under study (P>0.05). Male patients had a substantially higher level of CP (median, 20; range, 12–34) than female patients (median, 19; range, 10–33). Serum copper levels did not substantially correlate with other factors under study (P>0.05) (Table 6).

Discussion

Discussion

To stop the development of cirrhosis, AIH, a chronic liver disease, must be diagnosed early [15]. The majority of AIH patients appear with substantial fibrosis or even cirrhosis because there are no diagnostic markers for these patients [20]. When choosing a treatment plan and estimating the long-term prognosis for patients with AIH, it is crucial to assess the stages of liver fibrosis [21]. It is crucial to look for noninvasive indicators of liver fibrosis, and CP has been suggested as a fibrosis biomarker in several liver illnesses, including nonalcoholic fatty liver disease/steatohepatitis and chronic hepatitis B (CHB) [22]. To ascertain their clinical significance, more study is necessary because the involvement of serum CP and copper in fibrosis assessment in pediatric AIH is not well established. It is important to note that no research has examined the amounts of copper or CP in the serum of children with AIH. Therefore, the purpose of this study was to investigate whether serum copper and serum CP play a part in identifying liver fibrosis in children with AIH.

A H&E-stained slide of a patient with AIH showing significant portal fibrosis with the formation of portoportal connections (black arrows) and mild portal inflammation rich in plasma cells (blue arrow). (×200), An H&E-stained slide of a patient with AIH showing modest portal fibrosis (black arrow) and portal inflammation rich in plasma cells (blue arrow) (×200), An H&E-stained slide of a case of AIH showing considerable portal fibrosis (green arrows), cirrhosis and the development of regenerative nodules (black arrows), and mild portal inflammation rich in plasma cells (blue arrow). Zeng et al. [22] and Faddan et al. [23] reported a female-to-male ratio of 2.4:1 in a cohort of 34 children, while studies from Argentina showed an even higher ratio of 4:1 in adults. These findings are consistent with the female predominance in AIH identified in our study. However, Oettinger et al. [24] observed an equal male-to-female ratio (1:1) throughout the United States, indicating diversity in sex distribution. Notwithstanding these regional variations, most of the research indicates that women are more likely to have AIH, which supports the condition's status as an autoimmune disease. Additionally, seronegative AIH was found in only 16% of cases in our sample, whereas AIH-1 and AIH-2 accounted for 75% and 9% of cases, respectively [24-26], who also reported AIH-1 as the prevalent form, concur with our study's increased frequency of AIH-1 relative to AIH-2. According to Maggiore et al. [27], a strong index of suspicion is necessary for identifying seronegative AIH because it can be difficult to start corticosteroid treatment when there are no detectable autoantibodies. According to Faddan et al. [23], children with AIH-2 were considerably younger than those with AIH-1 in terms of age of diagnosis. Similarly, children with AIH-1 tend to be older than those with AIH-2, according to Bellomo-Brandão et al. [28] in the British cohort.

Compared to AIH-1 and seronegative AIH, patients with AIH-2 were younger in our group. However, because the P value was 0.082, this difference did not approach statistical significance. According to our research, patients with severe fibrosis had a much lower serum CP level than those without the disease. However, compared to patients in nonadvanced stages, those with advanced fibrosis have much higher serum copper levels. Additionally, children with type 2 AIH had considerably lower serum CP levels than children with type 1 and seronegative AIH. However, there was no statistically significant difference in copper levels between seronegative AIH, type 1, and type 2. These results are consistent with those of Raouf [29], who found that children with chronic liver disease (CLD) had noticeably higher serum copper levels than controls. This discovery was also highlighted by Sayed et al. [30], who found comparable results in a rural community in Egypt, and Roberts and Schilsky [31], who discovered higher serum copper levels in cirrhotic patients. According to this research, elevated serum copper might not be a specific indicator of Wilson disease but rather a common characteristic of liver disorders. As first described by Sternlieb and Scheinberg [32], CP is an alpha-2 glycoprotein that is mostly produced in the liver and is known for its function in acute phase reactions, where serum levels usually increase after inflammation or tissue injury. Our results, however, are more in line with those of Walshe [33] and Perman et al. [34], who noted lower CP levels in diseases like decompensated cirrhosis, fulminant hepatitis, and severe hepatitis. This suggests that CP reduction may be linked to compromised hepatic synthetic function rather than just the inflammatory stimulus. In a similar vein, Zeng et al. [35] found a strong relationship between CP levels and the severity of liver inflammation, demonstrating that CP levels significantly decreased in moderate or severe inflammation (grades 3–4) when there was widespread hepatocyte necrosis. This confirms our finding that lower serum CP levels are a result of moderate to severe liver injury, which is in line with the liver's impaired capacity to produce CP in advanced fibrosis. Ebara et al. [36] found that HCV-positive patients with chronic hepatitis or cirrhosis had higher copper levels in their liver parenchyma, which increased CP's oxidation activity. This finding partially supports our findings. Similarly, Ranganathan et al. [37] postulated that hepatic copper overload may contribute to the development of hepatocellular carcinoma by increasing the metalation of the CP protein, which results in a higher fraction of its active holo form. Our findings were corroborated by Zeng et al. [35], who found that CP was a unique biomarker that was adversely connected with liver fibrosis. They hypothesized that lower CP levels might result from a selective decrease in hepatocyte production as the fibrosis progressed. Our results, however, contrast with those of Habeeb et al. [38], who discovered an unanticipated rise in CP activity among HCV patients relative to HBV patients and observed no significant correlation between CP concentration and CLD caused by HBV and HCV. These disparities could be the result of changes in study methodology, patient demographics, or stages of illness. With an AUC of 0.945 (95% CI, 0.889–1.00) at a threshold of <17.5 ng/mL, our ROC analysis showed that CP is a highly sensitive marker for diagnosing liver fibrosis in juvenile AIH, attaining 97.3% sensitivity and 61.5% specificity. With an AUC of 0.939 (95% CI, 0.887–0.991) at a cutoff of >24.7 mg/dL, serum copper likewise demonstrated good performance, exhibiting 66.9% specificity and 90.8% sensitivity. These results imply that copper levels and CP levels may both be useful noninvasive methods for determining fibrosis in juvenile AIH. Our findings are corroborated by Zeng et al. [35] who reported AUCs of 0.74 for substantial fibrosis (F≥4), 0.75 for moderate fibrosis (F≥2), and 0.71 for advanced fibrosis (F≥3), indicating the use of CP in assessing fibrosis in CHB patients. Their investigation demonstrated CP's ability to lessen reliance on liver biopsies, especially in male patients, using a grading methodology akin to that of Scheuer et al. [39] and Bedossa [40]. The work of Zeng et al. [35] in CHB further supports the importance of CP as a trustworthy biomarker for liver fibrosis across various liver disorders, even though our study concentrated on pediatric AIH. Nonetheless, variability in patient groups and illness etiology may be reflected in disparities in cutoff values and diagnostic performance, indicating that the best thresholds should be confirmed clinical settings.

It is important to note that no research has examined the levels of copper or CP in the serum of children with AIH. There are certain restrictions on this study, though. First, the low prevalence of AIH means that there aren't many cases. Therefore, additional research with a sizable sample of AIH patients from several institutions is required to validate our findings.

In conclusion, this study concludes by indicating that blood CP and copper levels may provide useful information for identifying liver fibrosis in children with AIH. In the end, serum copper and CP levels ought to be considered as a component of a more comprehensive evaluation strategy for pediatric AIH patients.

Conflicts of interest

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Notes

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Notes

Author contribution

Conceptualization: SAMN, MIE, AEE, SSMK, MZH; Data curation: AEE, OMA, HAA, AABF, MAD; Formal analysis: MFH, AMA, AMGA, FMA; Funding acquisition: MAG, MAS, TIA, KHA; Methodology: IE, MMA, MZA, MFH, SSMK; Project administration: SAMN, AEE; Visualization: SAMN, MIE, AEE, MFH; Writing original draft: SAMN, AEE, MFH, SSMK; Writing review & editing: all authors.

Fig. 1.

(A) Moderate portal fibrosis with porto-portal link development (black arrows) and (B) mild portal inflammation rich in plasma cells (blue arrow) are visible on a hematoxylin and eosin (H&E)-stained slide of a patient with autoimmune hepatitis (AIH). An instance of AIH with modest portal fibrosis (black arrow) and mild portal inflammation rich in plasma cells (blue arrow) is depicted on an H&E-stained slide (×200), (C) An H&E-stained slide of a sample from a patient with AIH showing moderate portal inflammation rich in plasma cells (blue arrow), notable portal fibrosis (green arrows), cirrhosis, and regenerative nodules (black arrows) (×200), (D) An H&E-stained slide of a sample from a patient with AIH revealing modest portal inflammation with periportal glycogenotic nuclei (yellow arrow) and plasma cells (blue arrow) as well as significant portal fibrosis with the creation of porto-portal connections (black arrows).

Fig. 2.

Flowchart of enrolled children with autoimmune hepatitis (AIH).

Fig. 3.

Serum ceruloplasmin (A) and copper (B) levels by liver fibrosis stage. *P<0.05, statistically significant differences.

Fig. 4.

Receiver operating characteristic (ROC) analysis of ceruloplasmin (A) and serum copper levels (B) for the detection of liver fibrosis in children with chronic liver diseases. AUC, area under the curve; CI, confidence interval. *P<0.05, statistically significant differences.

References

1. Beretta-Piccoli BT, Mieli-Vergani G, Vergani D. Autoimmune hepatitis. In: Gershwin ME, Tsokos GC, Diamond B, editors. The rose and mackay textbook of autoimmune diseases. 7th ed. Academic Press, 2024:869-904.

2. Yu C, Wang W, Zhang Q, Jin Z. Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations. Front Immunol 2025;16:1510770
[Article] [PubMed] [PMC]

3. Sîrbe C, Badii M, Crişan TO, Bența G, Grama A, Joosten LAB, et al. Detection of novel biomarkers in pediatric autoimmune hepatitis by proteomic profiling. Int J Mol Sci 2023;24:7479
[Article] [PubMed] [PMC]

4. Saban OS, Vandriel SM, Fatima SA, Bourdon C, Mundh A, Ng VL, et al. Children with autoimmune hepatitis receiving standard-of-care therapy demonstrate long-term obesity and linear growth delay. Hepatol Commun 2025;9:e0624.
[PubMed] [PMC]

5. Heneghan MA, Lohse AW. Update in clinical science: autoimmune hepatitis. J Hepatol 2025;82:926–37.
[Article] [PubMed]

6. Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol 2019;31:1467–74.
[Article] [PubMed] [PMC]

7. Engel B, Diestelhorst J, Hupa-Breier KL, Kirchner T, Henjes N, Loges S, et al. Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis. Hepatol Int 2024;18:1214–26.
[Article] [PubMed] [PMC]

8. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–76.
[Article] [PubMed]

9. Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018;66:345–360.
[Article] [PubMed]

10. Kumari N, Kathuria R, Srivastav A, Krishnani N, Poddar U, Yachha SK. Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children. Eur J Gastroenterol Hepatol 2013;25:333–7.
[Article] [PubMed]

11. Lohse AW, Sebode M, Bhathal PS, Clouston AD, Dienes HP, Jain D, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int 2022;42:1058–69.
[PubMed]

12. Milkiewicz P, Saksena S, Hubscher SG, Elias E. Wilson’s disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol 2000;15:570–4.
[Article] [PubMed]

13. Witters P, Pirenne J, Aerts R, Monbaliu D, Nevens F, Verslype C, et al. Alpers syndrome presenting with anatomopathological features of fulminant autoimmune hepatitis. J Inherit Metab Dis 2010;33:451
[Article] [PubMed]

14. Veropalumbo C, Campanozzi A, De Gregorio F, Correra A, Raia V, Vajro P. Shwachman-Diamond syndrome with autoimmune-like liver disease and enteropathy mimicking celiac disease. Clin Res Hepatol Gastroenterol 2015;39:e1–4.
[Article] [PubMed]

15. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases. Hepatology 2020;72:671–722.
[Article] [PubMed]

16. Seo JK. Diagnosis of Wilson disease in young children: molecular genetic testing and a paradigm shift from the laboratory diagnosis. Pediatr Gastroenterol Hepatol Nutr 2012;15:197–209.
[Article] [PubMed] [PMC]

17. Kang NL, Zhang JM, Liu YR, Lin S, Dong J, Jiang JJ, et al. Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. Clin Res Hepatol Gastroenterol 2020;44:57–65.
[Article] [PubMed]

18. Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune hepatitis: a diagnostic and therapeutic overview. Diagnostics 2024;14:382
[Article] [PubMed] [PMC]

19. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116–28.
[PubMed]

20. Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med 2015;9:187–219.
[Article] [PubMed]

21. Chen Q, Gao M, Yang H, Mei L, Zhong R, Han P, et al. Serum ferritin levels are associated with advanced liver fibrosis in treatment-naive autoimmune hepatitis. BMC Gastroenterol 2022;22:23
[Article] [PubMed] [PMC]

22. Zeng DW, Dong J, Jiang JJ, Zhu YY, Liu YR. Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase. World J Gastroenterol 2016;22:9586–94.
[Article] [PubMed] [PMC]

23. Faddan NH, Abdel-Baky L, Aly SA, Hebat-allah GR. Clinicolaboratory study on children with auto-immune hepatitis in Upper Egypt. Arab J Gastroenterol 2011;12:178–83.
[Article] [PubMed]

24. Oettinger R, Brunnberg A, Gerner P, Wintermeyer P, Jenke A, Wirth S. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005;24:79–84.
[Article] [PubMed]

25. Jiménez-Rivera C, Ling SC, Ahmed N, Yap J, Aglipay M, Barrowman N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics 2015;136:e1237–48.
[Article] [PubMed]

26. Porta G, Carvalho E, Santos JL, Gama J, Borges CV, Seixas RBPM, et al. Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes. J Pediatr (Rio J) 2019;95:419–27.
[Article] [PubMed]

27. Maggiore G, Socie G, Sciveres M, Roque-Afonso AM, Nastasio S, Johanet C, et al. Seronegative autoimmune hepatitis in children: spectrum of disorders. Dig Liver Dis 2016;48:785–91.
[Article] [PubMed]

28. Bellomo-Brandão MA, Costa-Pinto EA, De Tommaso AM, Hessel G. Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients. Arq Gastroenterol 2006;43:45–9.
[Article] [PubMed]

29. Raouf AA, Radwan GS, Konsowa HA, Sira AM, Ibrahim NL. Serum zinc, copper, and iron in children with chronic liver disease. Egypt Liver J 2013;3:63–72.
[Article]

30. Sayed HA, El Ayyat A, El Dusoki H, Zoheiry M, Mohamed S, Hassan M, et al. A cross sectional study of hepatitis B, C, some trace elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt. J Egypt Public Health Assoc 2005;80:355–88.
[PubMed]

31. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089–111.
[Article] [PubMed]

32. Sternlieb I, Scheinberg IH. Ceruloplasmin in health and disease. Ann N Y Acad Sci 1961;94:71–6.
[Article]

33. WALSHE JM. Studies on the oxidase properties of ceruloplasmin: factors in normal and Wilson's-disease serum affecting oxidase activity. J Clin Invest 1963;42:1048–53.
[Article] [PubMed] [PMC]

34. Perman JA, Werlin SL, Grand RJ, Watkins JB. Laboratory measures of copper metabolism in the differentiation of chronic active hepatitis and Wilson disease in children. J Pediatr 1979;94:564–8.
[Article] [PubMed]

35. Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, et al. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One 2013;8:e77942.
[Article] [PubMed] [PMC]

36. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, et al. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus reference to hepatocellular carcinoma. Oncology 2003;65:323–30.
[Article] [PubMed]

37. Ranganathan PN, Lu Y, Jiang L, Kim C, Collins JF. Serum ceruloplasmin protein expression and activity increases in iron-deficient rats and is further enhanced by higher dietary copper intake. Blood 2011;118:3146–53.
[Article] [PubMed] [PMC]

38. Habeeb MH, Ewadh MJ, Mousa MJ. Ceruloplasmin activity and ferritin in patients with chronic liver disease. Med J Babylon 2021;18:257–60.
[Article]

39. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis 2002;6:335–47, v-vi.
[Article] [PubMed]

40. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15–20.
[Article] [PubMed]